Ceribell, Inc. (CBLL) stock
CBLLNasdaqElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 6/30134% above fair value
$26.14−0.21 (-0.80%)
Close on Nov 13, 2026Market cap $1.00BP/E –Yield –
Ceribell r&d expenses
Research and development expenses are spending on new products and technology.
Ceribell's R&D Expenses for the twelve months ending Jun 30, 2026 was $22.95M, up 39.9% year over year. For fiscal 2025 it was $19.14M, up 41.2% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $19.14M | +41.2% |
| FY2024 | Dec 31, 2024 | $13.56M | +50.8% |
| FY2023 | Dec 31, 2023 | $9.00M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $6.75M | +39.1% |
| Q1 FY2026 | Mar 31, 2026 | $6.16M | +45.1% |
| Q4 FY2025 | Dec 31, 2025 | $5.06M | +29.4% |
| Q3 FY2025 | Sep 30, 2025 | $4.98M | +46.8% |
| Q2 FY2025 | Jun 30, 2025 | $4.85M | +48.4% |
| Q1 FY2025 | Mar 31, 2025 | $4.25M | +42.3% |
| Q4 FY2024 | Dec 31, 2024 | $3.91M | +45.6% |
| Q3 FY2024 | Sep 30, 2024 | $3.40M | +47.1% |
| Q2 FY2024 | Jun 30, 2024 | $3.27M | – |
| Q1 FY2024 | Mar 31, 2024 | $2.98M | – |
| Q4 FY2023 | Dec 31, 2023 | $2.69M | – |
| Q3 FY2023 | Sep 30, 2023 | $2.31M | – |
See a number that looks wrong?